Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Michiel van den Brekel The Netherlands Cancer Institute
Vocal and pulmonary rehabilitation after total laryngectomy
Nirmesh Patel Cambridge Cancer Genomics
Monitoring cancer evolution through smart genomics and liquid biopsies
Chris Curtis The Swallows Head & Neck Cancer Charity
A patient’s journey ‘Cancer to the palace in 6yrs’
Dr Ioanna Nixon Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde
When the oncologist meets the patient: value of compassion. How well are we doing?
Dr Christy Goldsmith Action Radiotherapy
Improving patient outcomes with Stereotactic Ablative Body Radiotherapy (SABR)